Nurix Therapeutics (NASDAQ:NRIX) Shares Gap Down After Analyst Downgrade

Nurix Therapeutics, Inc. (NASDAQ:NRIX – Get Free Report) gapped down prior to trading on Wednesday after Wells Fargo & Company lowered their price target on the stock from $25.00 to $20.00. The stock had previously closed at $25.82, but opened at $17.16. Wells Fargo & Company currently has an overweight rating on the stock. Nurix Therapeutics shares last traded at $15.1510, with a volume of 2,143,441 shares trading hands.

Other equities research analysts have also issued research reports about the company. Mizuho boosted their price target on Nurix Therapeutics from $30.00 to $34.00 and gave the stock an “outperform” rating in a research note on Monday, July 13th. Wall Street Zen raised Nurix Therapeutics from a “hold” rating to a “buy” rating in a report on Saturday, October 17th. UBS Group boosted their target price on Nurix Therapeutics from $23.00 to $31.00 and gave the stock a “buy” rating in a research report on Wednesday, July 22nd. Truist Financial lowered their target price on Nurix Therapeutics from $34.00 to $33.00 and set a “buy” rating on the stock in a report on Tuesday, October 13th. Finally, Royal Bank Of Canada lowered their target price on Nurix Therapeutics from $36.00 to $35.00 and set an “outperform” rating on the stock in a report on Tuesday, October 13th. Fourteen equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $34.43.

Get Our Latest Stock Report on NRIX

Insider Buying and Selling

In related news, CFO Hans van Houte sold 4,769 shares of the company’s stock in a transaction that occurred on Wednesday, November 4th. The stock was sold at an average price of $15.63, for a total value of $74,539.47. Following the sale, the chief financial officer owned 42,745 shares of the company’s stock, valued at approximately $668,104.35. This represents a 10.04% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Julia Gregory sold 22,583 shares of the stock in a transaction on Wednesday, October 14th. The shares were sold at an average price of $23.40, for a total value of $528,442.20. Following the sale, the director owned 10,750 shares in the company, valued at approximately $251,550. This trade represents a 67.75% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 38,499 shares of company stock worth $893,645 in the last ninety days. Insiders own 6.70% of the company’s stock.

Key Stories Impacting Nurix Therapeutics

Here are the key news stories impacting Nurix Therapeutics this week:

  • Positive Sentiment: Nurix plans to present new and updated Phase 1a/1b data on bexobrutideg (NX-5948), its investigational BTK degrader for relapsed or refractory CLL/SLL, at the ASH annual meeting. The presentation may provide investors with fresh information on a key pipeline program, though the announcement does not disclose the results. Company announcement
  • Neutral Sentiment: CFO Hans van Houte sold 4,769 shares under a pre-arranged Rule 10b5-1 plan. The sale reduced his holdings by about 10%, but the planned nature of the transaction makes it less clearly a signal of a change in his outlook. Insider sale report
  • Negative Sentiment: Sanofi discontinued development of SAR448272, a STAT6 degrader licensed from Nurix. The loss of a partnered program is the clearest near-term negative catalyst for NRIX; reporting indicates the decision was not related to the STAT6 target itself. BioSpace report
  • Negative Sentiment: Wells Fargo lowered its price target from $25 to $20, although it retained an “overweight” rating. The cut reflects reduced expectations, even as the rating signals continued optimism. Report on the price-target change

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in the company. Fifth Third Bancorp boosted its stake in Nurix Therapeutics by 613.8% in the 3rd quarter. Fifth Third Bancorp now owns 1,556 shares of the company’s stock worth $37,000 after buying an additional 1,338 shares during the last quarter. Allspring Global Investments Holdings LLC grew its holdings in Nurix Therapeutics by 7.7% in the 3rd quarter. Allspring Global Investments Holdings LLC now owns 14,916 shares of the company’s stock valued at $348,000 after buying an additional 1,072 shares during the period. AlphaCentric Advisors LLC grew its holdings in Nurix Therapeutics by 4.5% in the 3rd quarter. AlphaCentric Advisors LLC now owns 27,006 shares of the company’s stock valued at $640,000 after buying an additional 1,161 shares during the period. Mirae Asset Global Investments Co. Ltd. acquired a new position in shares of Nurix Therapeutics during the 3rd quarter valued at about $126,000. Finally, China Universal Asset Management Co. Ltd. increased its stake in shares of Nurix Therapeutics by 15.1% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 18,936 shares of the company’s stock valued at $448,000 after acquiring an additional 2,479 shares during the last quarter.

Nurix Therapeutics Stock Performance

The company’s fifty day moving average price is $24.49 and its two-hundred day moving average price is $20.23. The firm has a market capitalization of $1.62 billion, a PE ratio of 6.42 and a beta of 1.80.

Nurix Therapeutics (NASDAQ:NRIX – Get Free Report) last released its earnings results on Tuesday, October 13th. The company reported $4.73 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.60) by $5.33. Nurix Therapeutics had a net margin of 42.01% and a return on equity of 49.34%. The firm had revenue of $673.06 million during the quarter, compared to the consensus estimate of $24.35 million. On average, equities analysts expect that Nurix Therapeutics, Inc. will post 1.14 earnings per share for the current year.

Nurix Therapeutics Company Profile

(Get Free Report)

Nurix Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing medicines that regulate the activity and abundance of proteins involved in cancer and immune-related diseases. Its research is based on targeted protein modulation, including the use of the ubiquitin-proteasome system and E3 ligases to selectively eliminate or modify disease-causing proteins.

The company’s pipeline includes oral targeted protein degraders and other small-molecule therapies. Its investigational programs include NX-5948, a Bruton’s tyrosine kinase (BTK) degrader being studied in B-cell malignancies and autoimmune diseases, and NX-2127, an orally administered BTK degrader designed to combine BTK degradation with immune-system modulation.

Featured Articles

Receive News & Ratings for Nurix Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nurix Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.